These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34909677)

  • 1. ATP citrate lyase inhibitor Bempedoic Acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score.
    Sanjay KV; Vishwakarma S; Zope BR; Mane VS; Mohire S; Dhakshinamoorthy S
    Curr Res Pharmacol Drug Discov; 2021; 2():100051. PubMed ID: 34909677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in
    Samsoondar JP; Burke AC; Sutherland BG; Telford DE; Sawyez CG; Edwards JY; Pinkosky SL; Newton RS; Huff MW
    Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):647-656. PubMed ID: 28153881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bempedoic acid as a PPARα activator: new perspectives for hepatic steatosis treatment in a female rat experimental model.
    Bentanachs R; Velázquez AM; Sánchez RM; Alegret M; Laguna JC; Roglans N
    Clin Investig Arterioscler; 2022; 34(2):57-67. PubMed ID: 34887111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice.
    Desjardins EM; Wu J; Lavoie DCT; Ahmadi E; Townsend LK; Morrow MR; Wang D; Tsakiridis EE; Batchuluun B; Fayyazi R; Kwiecien JM; Tsakiridis T; Lally JSV; Paré G; Pinkosky SL; Steinberg GR
    Cell Rep Med; 2023 Sep; 4(9):101193. PubMed ID: 37729871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bempedoic Acid Unveils Therapeutic Potential in Non-Alcoholic Fatty Liver Disease: Suppression of the Hepatic PXR-SLC13A5/ACLY Signaling Axis.
    Sun Q; Guo Y; Hu W; Zhang M; Wang S; Lei Y; Meng H; Li N; Xu P; Li Z; Lin H; Huang F; Qiu Z
    Drug Metab Dispos; 2023 Dec; 51(12):1628-1641. PubMed ID: 37684055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis.
    Burke AC; Telford DE; Huff MW
    Curr Opin Lipidol; 2019 Feb; 30(1):1-9. PubMed ID: 30586346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review.
    Feng X; Zhang L; Xu S; Shen AZ
    Prog Lipid Res; 2020 Jan; 77():101006. PubMed ID: 31499095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review.
    Duarte Lau F; Giugliano RP
    JAMA Cardiol; 2023 Sep; 8(9):879-887. PubMed ID: 37585218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bempedoic acid: effect of ATP-citrate lyase inhibition on low-density lipoprotein cholesterol and other lipids.
    Paton DM
    Drugs Today (Barc); 2020 Sep; 56(9):573-582. PubMed ID: 33025951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 12. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
    Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
    BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia.
    Morrow MR; Batchuluun B; Wu J; Ahmadi E; Leroux JM; Mohammadi-Shemirani P; Desjardins EM; Wang Z; Tsakiridis EE; Lavoie DCT; Reihani A; Smith BK; Kwiecien JM; Lally JSV; Nero TL; Parker MW; Ask K; Scott JW; Jiang L; Paré G; Pinkosky SL; Steinberg GR
    Cell Metab; 2022 Jun; 34(6):919-936.e8. PubMed ID: 35675800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterozygous knockout of Bile salt export pump ameliorates liver steatosis in mice fed a high-fat diet.
    Okushin K; Tsutsumi T; Ikeuchi K; Kado A; Enooku K; Fujinaga H; Yamauchi N; Ushiku T; Moriya K; Yotsuyanagi H; Koike K
    PLoS One; 2020; 15(8):e0234750. PubMed ID: 32785220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis
    Li H; Xi Y; Liu H; Xin X
    Front Nutr; 2022; 9():914079. PubMed ID: 36091227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action.
    Roglans N; Laguna JC; Alegret M
    Curr Opin Lipidol; 2023 Aug; 34(4):141-146. PubMed ID: 36942869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-type natriuretic peptide (CNP) in endothelial cells attenuates hepatic fibrosis and inflammation in non-alcoholic steatohepatitis.
    Bae CR; Hino J; Hosoda H; Miyazato M; Kangawa K
    Life Sci; 2018 Sep; 209():349-356. PubMed ID: 30114411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventive effect of trans-chalcone on non-alcoholic steatohepatitis: Improvement of hepatic lipid metabolism.
    Karimi-Sales E; Ebrahimi-Kalan A; Alipour MR
    Biomed Pharmacother; 2019 Jan; 109():1306-1312. PubMed ID: 30551380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of hepatic function using dynamic contrast-enhanced magnetic resonance imaging in melanocortin 4 receptor-deficient mice as a model of nonalcoholic steatohepatitis.
    Yamada T; Kashiwagi Y; Rokugawa T; Kato H; Konishi H; Hamada T; Nagai R; Masago Y; Itoh M; Suganami T; Ogawa Y; Abe K
    Magn Reson Imaging; 2019 Apr; 57():210-217. PubMed ID: 30465867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.